Literature DB >> 8138912

Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane.

B B Hasinoff1.   

Abstract

The hydrolysis of the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] to its presumed active form under conditions of physiologic pH and temperature were followed by HPLC chromatography. Successful chromatography of all of the hydrolysis products required the use of EDTA in the aqueous eluant to prevent metals in the HPLC flow system from binding to the strongly metal ion-binding product ADR-925. The kinetics of the hydrolysis was followed to approximately 200 h. The ring closest to the methyl group on ICRF-187 was observed to open at about twice the rate of the other ring. This product accumulates in the reaction mixture not only because it is produced more quickly but also because it decays more slowly. ICRF-187 is lost from the reaction mixture with a half-life of 9.3 h, whereas the final hydrolysis product ADR-925 is produced with a half-life of 23.0 h. Rate constants for ring opening to one-ring and two-ring opened hydrolysis products were obtained with a reaction scheme that assumed parallel and consecutive first-order reactions for these steps.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8138912     DOI: 10.1002/jps.2600830115

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes.

Authors:  J L Buss; B B Hasinoff
Journal:  Agents Actions       Date:  1993-09

2.  Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics.

Authors:  Evert L de Beer; Antonio E Bottone; Maartje C van Rijk; Jolanda van der Velden; Emile E Voest
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

3.  Scavenging effects of dexrazoxane on free radicals.

Authors:  Zhang Junjing; Zhao Yan; Zhao Baolu
Journal:  J Clin Biochem Nutr       Date:  2010-10-29       Impact factor: 3.114

Review 4.  Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.

Authors:  L R Wiseman; C M Spencer
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 5.  Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.

Authors:  Martin Stěrba; Olga Popelová; Anna Vávrová; Eduard Jirkovský; Petra Kovaříková; Vladimír Geršl; Tomáš Simůnek
Journal:  Antioxid Redox Signal       Date:  2012-10-12       Impact factor: 8.401

6.  Dexrazoxane Shows No Protective Effect in the Acute Phase of Reperfusion during Myocardial Infarction in Pigs.

Authors:  Pranitha Kamat; Stijn Vandenberghe; Stephan Christen; Anjan K Bongoni; Bernhard Meier; Robert Rieben; Ahmed A Khattab
Journal:  PLoS One       Date:  2016-12-21       Impact factor: 3.240

7.  UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study.

Authors:  Petra Reimerová; Anna Jirkovská; Hana Bavlovič Piskáčková; Galina Karabanovich; Jaroslav Roh; Tomáš Šimůnek; Petra Štěrbová-Kovaříková
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.